Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two…
Read More »pharmaceutical
Beijing’s new rules for state-led bulk tendering of medical drugs are the latest example of its “anti-involution” drive to combat…
Read More »
Beijing’s plan to publish China’s first list of innovative drugs eligible for coverage by commercial health insurance will draw keen…
Read More »
A potential multibillion-dollar deal unveiled on Friday by CSPC Pharmaceutical Group is the latest in a growing number of agreements…
Read More »
Shares of Chinese digital healthcare company ClouDr Group surged for a second day after it announced that it has embedded…
Read More »
HutchMed aims to establish a bigger presence in the city when the first wet laboratories at the much larger Hong…
Read More »
China’s biotechnology merger and acquisition (M&A) transactions have almost doubled this year, with interest perking up among investors amid a…
Read More »
Evive Biotech, a unit of Shenzhen-listed Yifan Pharmaceutical, aims to break the dominance of American drugs developer Amgen in the…
Read More »
The dietary supplement producer, established in 2004, spent 2 billion yuan (US$294 million) to build a factory this year in…
Read More »
Hutchison China MediTech (Chi-Med), whose stock has surged 70 per cent in London over the past six months, expects to…
Read More »